Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.75 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | CNR1 | P21554 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.49 |
| ▸ | ELANE | P08246 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL23610493 | 0.98 | KMT2A (0.73) | KMT2AALDH1A1CYP2C19SMN1; SMN2LMNA | |
| SCHEMBL13879509 | 0.87 | KMT2A (0.91) | KMT2AALDH1A1CYP2C19SMN1; SMN2LMNA | |
| SCHEMBL3248953 | 0.86 | ALDH1A1 (0.57) | KMT2AALDH1A1SMN1; SMN2LMNAMAPK1 | |
| SCHEMBL6623779 | 0.85 | KMT2A (0.55) | KMT2AALDH1A1SMN1; SMN2LMNAMEN1 | |
| SCHEMBL14197242 | 0.85 | ALDH1A1 (0.56) | KMT2AALDH1A1SMN1; SMN2LMNAMAPK1 | |
| Hydrochloric Acid SCHEMBL4830876 | 0.84 | ALDH1A1 (0.55) | KMT2AALDH1A1SMN1; SMN2LMNAMAPK1 | |
| SCHEMBL3233520 | 0.83 | KMT2A (0.73) | KMT2AALDH1A1CYP2C19SMN1; SMN2LMNA | |
| SCHEMBL21764931 | 0.82 | ALDH1A1 (0.53) | KMT2AALDH1A1SMN1; SMN2LMNAMAPK1 | |
| SCHEMBL9965983 | 0.82 | KMT2A (0.71) | KMT2AALDH1A1CYP2C19SMN1; SMN2LMNA | |
| Hydrochloric Acid SCHEMBL21753322 | 0.81 | ALDH1A1 (0.52) | KMT2AALDH1A1SMN1; SMN2LMNAMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11572370-B2 | CD16A binding agents and uses thereof | BIOHAVEN THERAPEUTICS LTD. (US) | 2023-02-07 | — | — | US | disclosed |
| WO-2019136442-A1 | CD16A BINDING AGENTS AND USES THEREOF | KLEO PHARMACEUTICALS, INC. (US) | 2019-07-11 | — | — | WO | disclosed |
| WO-2010022055-A2 | INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS | AMGEN INC. (US) | 2010-02-25 | — | — | WO | disclosed |
| WO-2010022055-A2 | INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS | AMGEN INC. (US) | 2010-02-25 | — | — | WO | disclosed |
| EP-0891332-B1 | 6-PHENYLPYRIDYL-2-AMINE DERIVATIVES | PFIZER (US) | 2004-03-17 | — | — | EP | disclosed |
| US-6465491-B2 | NITRIC OXIDE SYNTHASE INHIBITOR; NERVOUS SYSTEM DISORDERS | PFIZER INC. | 2002-10-15 | — | — | US | disclosed |
| US-20010034348-A1 | 6-phenylpyridyl-2-amine derivatives | LOWE JOHN A (US) | 2001-10-25 | — | — | US | disclosed |
| US-6235747-B1 | NITRIC OXIDE SYNTHASE INHIBITOR | PFIZER INC. | 2001-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010034348-A1 | 6-phenylpyridyl-2-amine derivatives | NOS2, NOS3, NOS1 | KMT2A 1323/4885ALDH1A1 1322/4885CYP2C19 624/4885 |
| US-11572370-B2 | CD16A binding agents and uses thereof | FCGR1A, FCGR2A, FCGR3B | KMT2A 499/4885ALDH1A1 1203/4885CYP2C19 3692/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.